Sedana Medical submits IND for US clinical trials
STOCKHOLM, Nov. 24, 2021 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA), with the aim to commence its phase III pivotal clinical...
Read more »